Examiner Cite

No

1

Initial*

5

Patent Number

Kind

publisher, city and/or country where published.

Code1

Issue Date

Remove

Figures Appear

Pages.Columns.Lines where

Relevant Passages or Relevant

Τ۶

	Application Number		10599050	
	Filing Date		2007-06-29	
NFORMATION DISCLOSURE	First Named Inventor Kazuya Hosokawa		ya Hosokawa	
STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Art Unit		1656	
Not for submission under 57 of K 1.337	Examiner Name	TSAY	, MARSHA M	
	Attorney Docket Number		JCLA21671	

U.S. PATENTS

Name of Patentee or Applicant

of cited Document

If you wish	n to a	dd a	idditional U.S. Pater	nt citatio	n intorm	ation pl	ease click the	Add button.		Add	
				U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*				t Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear							
	1									<u> </u>	
If you wish	h to a	dd a	dditional U.S. Publi	shed Ap	plication	n citatio	n information	please click the Ad	d butto	n. Add	
					FORE	GN PAT	ENT DOCUM	MENTS		Remove	
Examiner Cite Foreign Document Country Kind Put Initial* No Number3 Code2 i Code4 Dat		Publication Date	Name of Patentee or Applicant of cited Document Passages or Relevant Passages or Relevant Figures Appear		TA						
	1										
If you wis	h to a	dd a	dditional Foreign Pa				information p		buttor	Add Remove	_
		Inc	rlude name of the a						nnroni	riate), title of the item	
Examiner	Cite		nade name of the ti	anios (mi	O 4 117		LI (0), auc 0		ppiopi	nate), eec of the item	_

(book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s),

Initials* No

	Application Number		10599050	
	Filing Date		2007-06-29	
	First Named Inventor Kazuya Hosokawa		ya Hosokawa	
	Art Unit		1656	
(Not for Sashinssion diluter of Gric 1.33)	Examiner Name	TSAY	, MARSHA M	
	Attorney Docket Number		JCLA21671	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor Art Unit Examiner Name	TSAY	1656 , MARSHA M	

	1	*Office Action of Japan counterpart application*, issued on June 14, 2011, with partial English Translation thereof, in which the listed reference was offed.				
	TSIANG ET AL, "Functional Mapping of the Surface Residues of Human Thrombin", THE JOURNAL OF BIOLOGICAL CHEMISTRY, July 14, 1995, Vol. 270, No. 28, p. 16854-p. 16963.					
M		de destinant de la contrata del contrata del contrata de la contrata del contrata del contrata de la contrata de la contrata de la contrata de la contrata del		1		

EXAMINER SIGNATURE

Date Considered

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Oodes of USPTO Patent Documents at www.USPTO.GDV or MPEP 801 D.R. *Enter office that issued the document, by the two-letter code (WIPO Social of 13). *For Japanese patent documents, the advisable of the year of the entry of the Emparent must praced the sent number of the patent document. The patent document. The patent document with the patent document with the patent document with the patent document. Applicant to by patent document with the pa

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10599050
Filing Date		2007-06-29
First Named Inventor Kazu		ya Hosokawa
Art Unit		1656
Examiner Name TSAY		, MARSHA M
Attorney Docket Numb	er	JCLA21671

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
X	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
	information displacate statement. Con 27 CED 1 07(a)/1)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a
foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
after making reasonable inquiry, no item of information contained in the information disclosure statement was known to
any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure
statement. See 37 CFR 1.97(e)(2).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
-

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Belinda Lee/	Date (YYYY-MM-DD)	2011-08-11
Name/Print	Reinda Lee	Registration Number	46863

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiling. U.S. Operatment of Commence, P. 0. Box 1450, Alexandrin, V.S. 2313-1450. DING YESPTO SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandrin, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbra; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested requirement of the patient of the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, oursyant to 5 U.S.C. S52a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
 the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record
 may be disclosed, subject to the limitations of 37 CFR 11, 4s as routine use, to the public if the record was filed in
 an application which became abandoned or in which the proceedings were terminated and which application is
 referenced by whither a published application is application open to public inscredions or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.